Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...
BOSTON, January 15, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to ...
Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the ...
News Medical on MSN7d
New target identified for potential colorectal cancer treatmentColorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the digestive system.
The possibility of a new therapy for colorectal cancer could be achieved by blocking DUSP6, a protein that is important for ...
Fintel on MSN15d
B of A Securities Upgrades Erasca (ERAS)Fintel reports that on January 7, 2025, B of A Securities upgraded their outlook for Erasca (NasdaqGS:ERAS) from Neutral to Buy. Analyst Price Forecast Suggests 84.78% Upside As of December 23, 2024, ...
Medical Xpress on MSN15d
New treatment option shows promise for severe hypertrophic cardiomyopathy in childrenTrametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...
Oncology announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan ...
Proliferating animal cells maintain a stable size distribution over generations despite fluctuations in cell growth and division size. Previously, we showed that cell size control involves both cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback